The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro Malin WickströmCaroline HaglundJoachim Gullbo PRECLINICAL STUDIES 06 October 2007 Pages: 195 - 204
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan Murugesan K. GounderAhamed S. NazarEric H. Rubin PRECLINICAL STUDIES 18 October 2007 Pages: 205 - 213
Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells Axel-Rainer HanauskeUlrike EismannMichael Lahn PRECLINICAL STUDIES 14 November 2007 Pages: 215 - 222
A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines Piotr JasinskiBrandon WelshArkadiusz Z. Dudek PRECLINICAL STUDIES 24 October 2007 Pages: 223 - 232
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia Olatoyosi M. OdenikeRichard A. LarsonWendy Stock PHASE I STUDIES 24 January 2008 Pages: 233 - 239
A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas Emily ChanDaniel MulkerinJordan Berlin PHASE I STUDIES 24 January 2008 Pages: 241 - 247
A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial Christopher W. LeeKarl BélangerLesley Seymour PHASE II STUDIES 26 October 2007 Pages: 249 - 255
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck Patricia A. TangLillian L. SiuEric Winquist PHASE II STUDIES 24 November 2007 Pages: 257 - 264
A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168) Jennifer J. KnoxSharlene GillLesley Seymour PHASE II STUDIES 15 January 2008 Pages: 265 - 272
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma Premal H. PatelG. Varuni KondaguntaRobert J. Motzer PHASE II STUDIES 27 December 2007 Pages: 273 - 276
Extrinsic nitric oxide donor partially reverses arginine deiminase induced cell growth inhibition through NFκB and Bcl-XL Jae Hong SeoHwa Jung SungJun Suk Kim SHORT REPORT 05 January 2008 Pages: 277 - 282
PPAR-γ ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo I.K. ChoiY.H. KimJ.H. Seo SHORT REPORT 27 December 2007 Pages: 283 - 288